SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

Core Viewpoint - Sera Prognostics Inc. reported its financial results for Q4 and full year 2024, highlighting a decrease in revenue and net loss, while emphasizing progress in its PRIME study and recent fundraising efforts to support its mission in maternal and neonatal health [1][3]. Financial Results Summary Fourth Quarter 2024 - Revenue for Q4 2024 was $24,000, down from $41,000 in Q4 2023 [4]. - Total operating expenses increased to $9.4 million, a 6% rise from $8.9 million in Q4 2023 [4]. - Research and development expenses were $3.1 million, a decrease of approximately 19% compared to Q4 2023 [5]. - Selling, general and administrative expenses rose to $6.3 million from $5.0 million in Q4 2023, driven by increased spending on commercial activities [5]. - The net loss for the quarter was $8.6 million, compared to $7.9 million in the prior-year quarter [5]. Full Year 2024 - Total revenue for the full year 2024 was $77,000, down from $306,000 in 2023 [6]. - Total operating expenses decreased to $36.7 million from $40.1 million in 2023 [6]. - Research and development expenses for 2024 were $14.7 million, down from $15.2 million in 2023 [8]. - Selling, general and administrative expenses for 2024 were $21.9 million, significantly reduced from $24.7 million in 2023 [8]. - The net loss for 2024 was $32.9 million, down from $36.2 million in 2023 [8]. PRIME Study Results - The PRIME study demonstrated a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in neonatal length of hospital stay among the modified intent-to-treat population [7]. - A broader intent-to-treat population showed a 20% reduction in NMI and a 22% reduction in NICU admissions [7]. Fundraising and Future Plans - The company raised $57.5 million through a public follow-on offering in February 2025, extending its cash runway through 2028 [7][9]. - Proceeds will be used to expand commercial efforts in selected U.S. geographies, partner with payers and providers, and prepare for expansion in the European Union [7]. Company Overview - Sera Prognostics is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [1][11]. - The PreTRM® Test is a key product that provides early risk prediction for spontaneous preterm birth, enabling proactive interventions [11][13].